Cullinan Therapeutics, Inc. (CGEM)
Develops immune cell therapies targeting autoimmune diseases and cancer.
$17.47+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+127.8%
The outlook
CGEM is trading near recent highs, sitting 86% of the way up its 52-week range and above both its 50- and 200-day moving averages. Analyst targets average 81% above the current price, reflecting notably bullish sentiment on the stock. The overall data shows a strong uptrend with confident analyst positioning.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range86% of the way from its 52-week low to high
Price targetAvg target +81% vs current price
Analyst price target
~12-month · 11 analysts$31.55average target+80.6% vs now
Now $17.47
Low $24.00High $38.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.07B
52-wk high
$19.43
52-wk low
$5.68
50-day avg
$16.17
200-day avg
$12.91
Trailing P/E
—